异丙托溴铵吸入剂与布地奈德混悬液联合治疗慢阻肺的效果观察

Effect of ipratropium bromide inhalation combined with budesonide suspension in the treatment of COPD

中文关键词: 异丙托溴铵吸入剂  布地奈德混悬液  慢阻肺  肺功能

英文关键词: Ipratropium bromide inhalation  Budesonide suspension  COPD  Pulmonary function

中文摘要:

      目的：探讨异丙托溴铵吸入剂联合布地奈德混悬液治疗慢阻肺（COPD）的临床效果。方法：研究对象为本院在2019年1月至2020年1月收治的50例COPD患者，根据治疗方法的差异将其分为单一组（n=25，予以异丙托溴铵吸入剂治疗）与联合组（n=25，在单一组基础上联合布地奈德混悬液治疗）。以两组治疗前肺功能、慢阻肺自我评估测试（CAT）、呼吸困难评分（MRC）改善情况为临床疗效评价指标。结果：联合组治疗后的峰值呼气流速（PEF）、第1秒用力呼气容积（FEV₁）、1秒钟用力呼气容积占用力肺活量%（FEV₁/FVC）水平高于单一组，而CAT评分、MRC评分均低于单一组（P＜0.05）。结论：采用异丙托溴铵吸入剂联合布地奈德混悬液治疗COPD的效果更为显著，不仅能有效改善患者呼吸困难症状，还能改善肺通气功能，预后效果良好。

英文摘要:

      Objective: To investigate the clinical effect of ipratropium bromide inhalation combined with budesonide suspension in the treatment of chronic obstructive pulmonary disease (COPD).Methods: The subjects were 50 patients with COPD admitted to our hospital from January 2019 to January 2020. They were divided into single group (n=25, treated with ipratropium bromide inhalation) and combination group (n=25, combined with budesonide suspension on the basis of single group). The improvement of pulmonary function, chronic obstructive pulmonary disease self-assessment test (CAT) and dyspnea score (MRC) of the two groups before treatment were used as the clinical evaluation indexes.Results: The peak expiratory flow rate (PEF), forced expiratory volume in the first second (FEV₁/ FVC) and forced expiratory volume in one second (FEV₁ / FVC) in the combined group were higher than those in the single group after treatment, while the CAT score and MRC score of the combined group were lower than those of the single group (P＜0.05).Conclusion: The effect of ipratropium bromide inhalation combined with budesonide suspension in the treatment of COPD is more significant. It can not only effectively improve the symptoms of dyspnea, but also improve the pulmonary ventilation function. The prognosis is good.